Is Brii Biosciences Limited (BRIBF) a Buy, Sell, or Hold?
OTC : BRIBF
Brii Biosciences Limited
$0.12575 USD
$0 (0.0%)
- Volume
- 4.15K
- Average Volume
- 238
- Market Capitalization
- $90.69M
- P/E Ratio
- -2.88
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $0.25
- Year Low
- $0.13
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $60.73
Company Overview
OTC
Zhi Hong
Biotechnology
Healthcare
BRIBF
75
CN
USD
Liquidity Metrics
0.00
60.73
60.73
18.83
0.00
Sales & Valuation
$18.12M
32.23
0.26
-1.99
-0.43
Profitability
-$0.3
-$216.88M
-1124.36%
-1122.05%
-8.92%
-9.19%
P/E Metrics
-2.88
-0.04
-0.04
Analyst Price Target & Rating
0/5
0 Analysts
%
Financial Health Scores
5.90
3/9
$1.93B
$2.36B
$36.22M
-$605.63M
Key Metrics (TTM)
$21.95M
1.14
-0.08
60.73
-8.92%
-12.68%
-35.01%
-50.21%
0 days
Company Executives
| Name | Title |
|---|---|
| Haifeng Cao | Head of China Development |
| Karen Del Barrio Neuendorff | Chief People Officer & Head of Human Resources |
| Wing Tsz FCIS | Joint Company Secretary |
| Sarah Qiu | Associate Director of Investor Relations |
| David Margolis | Chief Medical Officer |
| Ankang Li | COO, Joint Secretary & Executive Director |
| Brian Alvin Johns | Chief Scientific Officer |
| Qing Zhu | Head of Pre-clinical Sciences and Translational Research |
| Eleanor de Groot | Chief Technology Officer |
| Zhi Hong | Co-founder, Executive Chairman of the Board & Chief Executive Officer |
Poll Results
No votes yet today — be the first to share your view!
About Brii Biosciences Limited (OTC:BRIBF) Stock
Brii Biosciences Limited, established in 2017 and headquartered in Beijing, China, is dedicated to advancing therapeutic solutions for infectious diseases and disorders affecting the central nervous system. Their diverse pipeline includes BRII-778 and BRII-732, both progressing through Phase I clinical trials for HIV patients. For Hepatitis B (HBV), they are evaluating BRII-179 and BRII-835 in a combined Phase 2 study; BRII-179 also stands as a recombinant protein-based HBV immunotherapeutic in Phase 1b/2a, while BRII-835 has completed Phase 2 for chronic HBV patients. Additionally, the Amubarvimab/romlusevimab combination therapy is under development for COVID-19. In the CNS arena, BRII-296 targets postpartum depression (PPD) and BRII-297 addresses various depressive disorders. Their anti ... -infective portfolio features BRII-636, BRII-672, and BRII-693, designed to combat multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative infections, alongside BRII-658 for MDR/XDR tuberculosis and non-tuberculosis mycobacterial infections.
2026-05-27 07:00:00
- Final results from the ENSURE study demonstrate that the addition of elebsiran resulted in a higher functional cure rate compared with pegylated interferon alfa (PEG-IFNα) alone - Data from Cohort 4 suggested that participants responding to prior BRII ‑ 179 treatment achieved the most robust functional cure outcomes, further supporting its potential clinical benefit - Data from an ENSURE translational study demonstrated that BRII ‑ 179-induced epitope-mismatched CD4+ T cells and HBs ‑ specific B cell maturation were associated with enhanced HBsAg loss following curative treatment, offering additional insights into its potential mechanisms DURHAM, N.C. and BEIJING, May 27, 2026 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet medical need, today announced end-of-study (EOS) data from Cohorts 1-4 of its Phase 2 ENSURE study at the European Association for the Study of the Liver (EASL) Congress 2026 in Barcelona, Spain.
Brii Bio Presents Cross-Study Analysis of Post-Treatment HBsAg Rebound at APASL 2026
2026-04-26 07:00:00
- Participants achieving HBsAg loss with pegylated interferon alfa (PEG-IFNα) ± elebsiran or BRII-179 demonstrated favorable off-treatment clinical outcomes, with most HBsAg rebounds
Frequently Asked Questions
-
What is the current Brii Biosciences Limited (BRIBF) stock price?
-
Brii Biosciences Limited(OTC:BRIBF) stock price is $0.12575 in the last trading session. During the trading session, BRIBF stock reached the peak price of $0.2459 while $0.12575 was the lowest point it dropped to. The percentage change in BRIBF stock occurred in the recent session was 0.0% while the dollar amount for the price change in BRIBF stock was $0.
-
BRIBF's industry and sector of operation?
-
The OTC listed BRIBF is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of BRIBF?
-
Haifeng Cao | Head of China Development
Karen Del Barrio Neuendorff | Chief People Officer & Head of Human Resources
Wing Tsz FCIS | Joint Company Secretary
Sarah Qiu | Associate Director of Investor Relations
David Margolis | Chief Medical Officer -
How many employees does BRIBF have?
-
Number of BRIBF employees currently stands at 75. BRIBF operates from Building 7, Beijing, BE 100192, CN.
-
Link for BRIBF official website?
-
Official Website of BRIBF is: https://www.briibio.com
-
How do I contact BRIBF?
-
BRIBF could be contacted at phone #+86 10 8215 0666 and can also be accessed through its website. BRIBF operates from Building 7, Beijing, BE 100192, CN.
-
How many shares of BRIBF are traded daily?
-
The average number of BRIBF shares traded daily for last 3 months was 238.
-
What is the market cap of BRIBF currently?
-
The market value of BRIBF currently stands at $90.69M with its latest stock price at $0.12575